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1. Introduction
The list of primary immunodeficiencies (PID) includes now more than 200 different diseases
and syndromes characterised by dysfunction of immune system with different epidemiology
ranging from common, like selected IgA deficiency, to very rare, diagnosed in singular
patients. The deficiencies of humoral immunity are frequent including transient hypogam‐
maglobulinemia of infants (THI), common variable immunodeficiency (CVID), selected IgA
deficiency (IgAD), hyper IgM syndrome (hyperIgM) or agammaglobulinemia (XLA). The
hypogammaglobulinemia of selected immunoglobulins’ class (IgG or IgA) or all classes (e.g.
CVID) are associated with allergy and autoimmunity in significant percentage of patients. The
hypothesis explaining autoimmune diseases in humoral immunodeficiency includes presence
of autoreactive T and B lymphocytes, deregulation of immune response associated with
number and function of T regulatory cells and other mechanisms. The typical clinical symp‐
toms of autoimmune process in patients with humoral deficiency (CVID, IgAD, hyper IgM)
include cytopenias, gastrointestinal tract diseases like celiac or inflammatory bowel diseases,
endocrine system autoimmunity, rheumatoid arthritis and systemic autoimmune diseases.
The diagnosis of autoimmunity in humoral immunodeficiency is difficult, due to low produc‐
tion of antibodies, overlapping of clinical symptoms of immunodeficiency and autoimmunity.
Autoimmunity is noted also in group of well defined immunodeficiency or immunodysregu‐
lation syndromes with autoimmune symptoms as criteria of given immunodeficiency, e.g.,
autoimmune lymphoproliferative syndrome (ALSP) and Wiskott-Aldrich syndrome (WAS).
Therapy of autoimmunity in immunodeficient patients includes steroids, immunosuppres‐
sion, similar to patients without PID. However, if, in some patients with PID, the standard
therapy of autoimmune disease is not effective, the immunoglobulins in high dose and/or,
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monoclonal antibodies are used. Progress and severity of autoimmune process, resistance to
therapy, life-threatening symptoms are now the indications for haematopoietic stem cells
transplantation for these patients.
2. Introduction to primary immunodeficiency associated with
autoimmunity
The primary immunodeficiencies (PID) consist of more than 200 diseases with one common
background – dysfunction of immune system as effect of T, B lymphocytes, NK cells and
neutrophils’ disturbances in ontogeny and function. The first, most extreme group of PIDs are
severe combined immunodeficiencies (SCID) characterised by the lack of immunocompetent
cell populations. In these deficiencies, the different patterns of lack of cells are noted- without
T lymphocytes and/or NK cells (SCID T-B+NK-, SCID T-B+NK+), and/or B lymphocytes (SCID
T-B-NK-, SCID T-B-NK+). The one way to safe life of newborn babies and infants with SCID
is haematopoietic stem cells transplantation (HSCT) from matched related or unrelated donor
(Table 1). In SCID, the autoimmunity is rare, practically seen only in Omenn’s syndrome (Rag1/
Rag2 deficiency). In this type of SCID, besides antibacterial, antifungal, antiviral therapy,
substitution of immunoglobulins as standard therapy for SCID, the use of steroids and/or
cyclosporine A is indicated to resolve the erythrodermia and eosinophilia. This symptomatic
therapy is effective in majority of patients. Thrombocytopenia, neutropenia and leukopenia
are often due to hyperactivity of spleen.
Type of deficiency Laboratory data Genetic background Clinical features Effective therapy
T-B+
Gamma chain
deficiency
T, NK decreased, B
normal, low IgG
Defect of receptors for:
IL-2, -4, -7, -9, -15, -21,
X-linked
Severe infections
(bacterial, viral,
fungal), failure to
thrive
Antibiotics,
antimycotics, IVIG
substitution, HSCT as
curative
Other deficiency
with known genetic
background
like above JAK3, IL-7R alfa chain,
CD45 deficiency
Autosomal recessive
Like above Like above
T-B-(NK-)
Omenn’s syndrome
T, B, NK decreased, IgG
low, IgE high
RAG1/RAG2 Erythrodermia,
eosinophilia,
autoimmunity, CMV
infection,
splenomegaly
Steroids and/or
cyclosporine A, IVIG,
antibacterial, antiviral
therapy, HSCT
Reticular dysgenesis T, B, NK decreased, low
IgG
Adenylate kinase (AK2)
deficiency
Neutropenia, deafness Antibiotics,
antimycotics,
Antiviral therapy,
IVIG, HSCT
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Type of deficiency Laboratory data Genetic background Clinical features Effective therapy
Adenosine
deaminase
deficiency (ADA)
may be progressive
decrease of T, B, NK cells
number
ADA deficiency Costochondral
junction flaring,
neurological features,
hearing impairment,
lung and liver
involvement
Like above
MHC class I decreased CD8, normal
B and NK cells
TAP, TAP2 or TAPBP
mutation
Severe infections,
vasculitis
Like above
MHC class II decreased CD4, normal
B and NK cells number
Transcription factors
mutation (CIITA, RFX5,
RFXAP, RFXANK)
Infections, failure to
thrive, chronic
diarrhoea
Like above
Table 1. Selected types of severe combined immunodeficiencies (SCID) [acc. 1]
In general consensus, the primary immunodeficiencies are divided into groups depending on
the basic defect: humoral immunodeficiency –- common deficiency with prevalence of
disorders in immunoglobulins and antibodies production, cellular immunodeficiency and
well-defined syndromes of immunodeficiency with prevalence of cellular mechanisms leading
to functional deficiency. The bacterial, viral infections with severe clinical course and poor
response to therapy are common and typical symptoms of immune deficiency, due to lack of
proper reaction of immune system. In patients with SCID, these infections are life-threatening
and together with failure to thrive and weight gaining, they lead to death within first year of
life. The autoimmunity process and symptoms are noted as associated disease or complications
in different types of immune deficiency. The autoimmunity, in particular types of PID (e.g.
hyper IgM syndrome, autoimmune lymphoproliferative syndrome (ALPS), Wiskott-Aldrich
syndrome (WAS), is one of criteria of these immunodeficiencies (Table 2). In CVID, one of
common immune deficiency of immunoglobulin and specific antibodies synthesis, the
autoimmune co-existent process and diseases are noted in more than 30% of patients (up to
60% in different groups). The similar frequency of autoimmunity is observed within IgA
deficiency patients.
Type of deficiency Laboratory data Genetic background Clinical features Effective therapy
WAS
Wiskott-Aldrich
syndrome
Decreasing T
number, B normal,
IgA, IgE increased
Mutation in WAS
X-linked
Microthrombocytopenia,
eczema, autoimmunity, IgA
nephropathy, infections,
lymphoma
Antibiotics, antiviral
therapy, IVIG, HSCT
ALPS (defects of
apoptosis)
1.Fas defect (CD95)
2.FasL (CD95L)
Increased DNT
(CD3/CD4-/CD8-),
normal B
and NK cells
Mutation of
TNFRSF6 (surface
apoptosis receptor)
Lymphadenopathy,
splenomegaly, cytopenias,
high or normal IgG level
Steroids (often
resistance), high-dose
IgG, MMF, sirolimus,
HSCT
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Type of deficiency Laboratory data Genetic background Clinical features Effective therapy
3.Caspase 10
4. Caspase 8
Mutation TNFSF6
(Fas ligand)
Mutation of Casp10
(intracellular
apoptosis pathway)
Mutation of Casp8
Lymphadenopathy,
splenomegaly, cytopenias,
recurrent bacterial and viral
infections, low IgG
APECED, Polyendo-
crinopathy,
candidiasis,
enctodermal
dystrophy
T, B and NK cells
normal, IgG normal
Mutation of AIRE Autoimmunity of endocrinal
glands, chronic candidiasis,
hypoplasia of dental enamel
Symptomatic
supplementary
therapy, steroids
IPEX polyendocrino
pathy, enteropathy
Impaired function of
T regulatory, B and
NK cells normal,
high IgA, IgE
Mutation of FOXP3
X-linked
Autoimmune enteropathy,
diabetes, thyroiditis, eczema,
haemolytic anaemia,
thrombocytopenia
Symptomatic therapy
CD25 deficiency T, B and NK cells
normal
Mutation of IL-2
receptor alfa chain
Lymphoproliferation,
autoimmunity
Symptomatic therapy
Table 2. Diseases of immunodysregulation with autoimmunity [acc.1]
The primary immunodeficiency described below are selected from a list of known PIDs, based
on high frequency or obligatory occurrence of autoimmunity, before or during the course of
basic immunodeficiency disease [1-11].
2.1. Humoral immunodeficiency
X-linked agammaglobulinaemia (XLA, former name – Bruton’s disease) with Btk mutation
(Bruton’s tyrosinae kinase) is typical example of B lymphocyte ontogeny disturbances. The
inhibition of maturation between proB and preB cell stage, results in lack of mature B lym‐
phocytes in the periphery. The first symptoms, typically severe bacterial infections, are noted
after 4 months of life, when maternal IgG immunoglobulins have been used, without replace‐
ment by immunoglobulins produced by immune system of the affected patient. In serum, the
level of IgG, IgA and IgM is often below detection; B cells are below 1% of lymphocyte
population; T lymphocytes are normal in all aspects – total number, subpopulations’ ratio and
function. In part of XLA patients, the activation and function of NK cells are impaired.
Sometimes, the number of NK cells is very low, due to particular mutation of Btk, essential to
normal ontogeny of NK cells. In physical examination, the lack of B cell in periphery is seen
as small or absent tonsils and lymph nodes. Autoimmunity is very rare in XLA, but in singular
patients, rheumatoid arthritis or myositis symptoms were noted [12-15]. Within our group of
10 boys with XLA, the Shulman disease (eosinophilic fasciitis) was diagnosed in a 14-year-old
patient [case report in preparation].
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Hyper IgM syndrome (HIGM) is the name for a family of 5 different types of this immuno‐
deficiency, with X-linked form as the most severe. This X-linked type of hyper IgM syndrome
(HIGM1) is associated with T lymphocytes defect – lack of expression or function of CD40
ligand (CD40LG). The other forms of hyper IgM syndrome are results of mutation of genes
encoding: CD40 expression on B cells (HIGM3), activation-induced cytidine deaminase
(AICDA) (HIGM2), uracyl-N-glucosylase (UNG) (HIGM5). The signal transduction between T
and B lymphocytes are critical for proper response to pathogens, so the disturbances in this
function of lymphocytes explain the severe and recurrent bacterial infections in HIGM patients.
In laboratory, very low or undetectable levels of IgG, IgA, normal or increased level of IgM,
normal number of B and T lymphocytes are found. The other symptoms typical for hyper IgM
syndrome include leukopenia, mainly due to severe neutropenia, high sensitivity to infection
with Cryptosporidium parvum leading to sclerosing cholangitis and liver cirrhosis. In X-linked
type of hyper IgM syndrome, HSCT is suggested as curable procedure, especially for patients
with neutropenia refractory to G-CSF therapy, patients with cryptosporidiosis and severe
bacterial infections, e.g., osteomyelitis [16-19].
Selected  IgA  deficiency  (IgAD)  is  the  most  common  immunodeficiency  of  humoral
immunity (the mean frequency in Europe is 1/600 people). Diagnosis of IgAD is based on
low level (often below detection) of IgA, normal or compensatory high level of IgG, normal
level  of  IgM. IgAD is  observed in small  children (below 4 years of  age),  but the stable,
definite selected IgA deficiency is diagnosed in children older than 4 years. This time is
enough, like in transient hypogammaglobulinemia of infancy (THI), for development of the
immune system and correction of immunoglobulin deficiency including IgA. In IgAD, the
majority of  affected children (70–80%) are asymptomatic.  The remaining (20–30%) IgAD
patients  suffer  from  recurrent  infections,  mainly  of  the  respiratory  tract.  In  both  sub‐
groups of IgAD patients (with and without symptoms of immunodeficiency), allergic and
autoimmune diseases are noted. The respiratory and gastrointestinal tract is  involved in
majority  of  patients.  Recurrent  upper  respiratory  tract  infections  caused  by  different
bacteria, often encapsulated, are noted in younger children; prolonged sinusitis is typical
for older children, teenagers and adults.  The incidence of allergy in IgAD patients is  20
times higher than in healthy population with asthma, allergic rhinitis, conjunctivitis, food
allergy, atopic dermatitis and urticaria as typical features [5, 11, 20-23].
The pathogenesis of IgAD is based on the defective terminal maturation of B cells into IgA
secreting plasma cells, resulting in reduced levels of serum and secretory (mucosal) IgA (sIgA)
[5, 22]. The IgA circulating in serum consists of IgA1 and IgA2 subclasses. Depending on the
localisation of IgA production’, the monomeric and dimeric forms of IgA (with joining (J)-chain
in structure) are noted – monomeric circulating in serum, dimeric seen on surface of mucous
membranes of small and large intestine, respiratory and urinary tract. The sIgA is produced
by cells present within lymphoid tissue under the mucous membranes (MALT) [22, 24]. sIgA
composed of IgA2 molecules characterise high resistance to enzymatic digestion by bacterial
proteases. This secretory IgA immunoglobulin plays an important role in protection of mucous
membranes from pathogens present within the lumen by agglutinating activity and facilitating
the clearance of pathogens in the gastrointestinal, respiratory and urinary tracts [25]. Functions
of sIgA include direct neutralization of pathogens, intracellular neutralization of viruses
during transepithelial transport and inhibition of receptors-mediated activation of immune
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system. The role of sIgA in selection of antigens entering through the mucous membrane is
also postulated. The lack of sIgA on surface of mucous membranes is compensated by IgG and
IgM [22, 25].
Common variable immunodeficiency (CVID) presents variety of symptoms and heteroge‐
neous clinical profiles. CVID has a frequency of 1:25000 to 1:66000 people; however, the delay
of diagnosis is serious and estimated as years. Historically, the first description of CVID came
from adults with typical clinical symptoms noted in these patients. CVID is diagnosed in adults
and children older than 4 years of age (THI) after exclusion of all other known causes of
hypogammaglobulinemia. The criteria of CVID include hypogammaglobulinemia in one or
more classes of immunoglobulins (IgG only or IgG and IgA, and/or IgM), disturbances of
cellular immunity noted in majority of patients. The consequence of disorders in cellular
immunity (low number of T lymphocytes, reverse CD4:CD8 ratio, low response to stimulation
in vitro) and low production of immunoglobulins are poor responses to pathogens and vaccines
antigens [6, 8, 21, 25-31]. The hypogammaglobulinemia is a result of deregulation of B-cell
differentiation process and disturbances of T-cell regulatory function, including signalling
process and function of T-cell receptor. Number of B lymphocytes in peripheral blood and in
lymph nodes is usually within normal range, but the disturbances in maturation resulted in
decreased number of plasma cells and B memory cells. However, the low number of B cells,
even below 1%, is noted in minority of CVID patients (about 10%) [28], suggesting the
differential diagnosis of XLA if the patient is a boy with the level of immunoglobulins below
detection. The clinical severity of course of CVID (e.g. splenomegaly, bronchiectases, autoim‐
munity) is associated with the reduction of memory B cells number (CD19+CD27+IgD-)
observed in majority of CVID patients. To date, it is the one parameter with predictive value
for the clinical course of CVID [32, 33]. The search for genetic background of CVID resulted in
description of mutation in TACI gene (transmembrane activator and calcium-modulator) in
about 10% of patients. The role of TACI, as member of TNF-like receptor family, is transduction
of signals imported for cell survival, apoptosis and isotype switching. The ligands for TACI
are BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), both associated
with survival of autoreactive B-cell clones and overt autoimmunity. The mechanisms of BAFF
and APRIL activity include induction of isotype switching of B cells. The absence of TACI (their
receptor) resulted in inhibition of plasma cell maturation and inhibition of immunoglobulin
production [34]. Defects like TACI deficiency, BAFF deficiency, APRIL deficiency, loss of
inducible co-stimulator and others, led to heterogeneity of clinical features that were observed
in CVID patients. This genetic and clinical heterogeneity was the cause of named “variable”
this type of humoral deficiency and proposition of CVID subclassifications [5, 11, 35, 36].
The observations of CVID in children showed heterogeneity of clinical symptoms like in adults,
but the course of disease is often different. In a large study of 248 CVID patients (children and
adults), majority of them (90%) showed severe and recurrent infections, mostly in the respi‐
ratory tract [26]. Chronic lung disease developed in a reasonable number (27%) of adult
patients. Recurrent infections of lower respiratory tract may lead to the development of
bronchiectases. However, the bronchiectases may also be the result of few but severe and
prolonged lung infections. In young children, chronic lung disease and bronchiectases are rare.
Observations in a group of teenagers suggest that the time of CVID onset and duration are
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important for the occurrence of these complications. Moreover, in children with CVID,
lymphoid interstitial pneumonia (LIP), an unusual and rare type of lung disease, is observed
[37]. In our group of 52 children with CVID, the histology of lung biopsy showed LIP in 3
patients (2 boys and a girl). Chronic sinusitis, LIP or bronchiectases develop and progress
independently of regular substitution of IgG, even in higher doses [38, 39].
2.2. Cellular immunodeficiency with autoimmunity
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency and platelets disease
caused by mutation of gene WASP (WAS protein) (Table 2). The disease is characterised by
microthrombocytopenia (reduced platelets volume); eczema; high susceptibility to bacterial,
viral infections; autoimmunity and high frequency of lymphomas (mainly B cell origin) [40-43].
The defects of T lymphocytes include cytoskeletal disorders leading to paucity of surface
microvilli, defective polymerisation of actin, defective internalisation of CD3 after cross-
linking of T-cell receptor (TCR) resulting in poor response of T cell to stimulation [40, 41].
Typical clinical symptoms of WAS are: thrombocytopenia with poor response to immunoglo‐
bulins and/or steroids, infections with severe clinical course and eczema from mild to very
severe form, progressing with time. The other WASP gene mutations are associated with
thrombocytopenia or agranulocytosis resistant to therapy with steroids or G-CSF. For these
clinical syndromes, like for typical X-linked Wiskott-Aldrich syndrome, HSCT is suggested as
curative therapy [4, 5, 40, 42, 43].
Autoimmune lymphoproliferative syndrome (ALPS) belongs to a group of diseases associ‐
ated with immunoregulation and apoptosis disturbances (Table 2). The mutation of genes
regulating production of proteins responsible for apoptosis process induced by FAS is the basis
of this syndrome. Apoptosis disorders lead to polyclonal proliferation of T lymphocytes,
accumulation of these cells in lymph nodes and spleen, and severe autoimmune symptoms.
Clinical forms ALPS include: type Ia – mutation of FAS gene (CD95), autosomal dominating
type of heredity with typical symptoms and high risk of lymphomas; type Ib – mutation of
FAS ligand gene (CD95L), autosomal dominating or recessive heredity, often SLE and other
autoimmune diseases; type IIa – mutation of Caspase-10 gene, autosomal dominating showing
wide spectrum of autoimmune diseases; type IIb – mutation of Caspase-8 gene, autosomal
dominating, in clinic – bacterial and viral infections; type III – mutation of NRAS (neuroblas‐
toma ras viral oncogene homolog) activation gene coding protein binding GTP, autosomal
dominating with high risk of leukaemias and lymphomas [4, 5, 44-46]. In the laboratory,
increased percentage (and number) of double-negative T lymphocytes (DNT) with phenotype
CD3+/CD4-/CD8-, TCR α/β chains and decreased number of T regulatory cells are seen. These
DNT T lymphocytes showed high expression of HLA-DR as activation marker, weak response
to stimulation, expression of CD45 isoform. It is believed, that the low number of T regulatory
cells (Treg) is associated with autoimmune symptoms observed in patients. The B lymphocytes
showed low production of specific antibodies to pathogens, but high production of autoanti‐
bodies against platelets, neutrophils, erythrocytes, and less frequent, antibodies against cell
nuclei, phospholipids and rheumatoid factor. Production of autoantibodies is noted despite
lower number of B cells in peripheral blood [44-46]. Clinical manifestation of symptoms and
severity of disease course depend on type of ALPS and age of onset. The episodes of acute
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thrombocytopenia, haemolytic anaemia, splenomegaly (megaspleen) and chronic thrombo‐
cytopenia are severe, even life-threatening [44, 45, 47]. Steroids are first-line therapy in ALPS,
but, in almost half of patients, the results are transient with progress of lymphadenopathy and
splenomegaly. The ALPS patients resistant to steroids are treated with second-line therapy,
consisting of infusion of immunoglobulins in high doses (1.0–2.0 g/kg b.w.), mofetil myco‐
phenolate (MMF) and sirolimus. Good response is noted in about 40% of patients; for the
remaining, traditional suppression (vincristine, methotrexate, mercaptopurine), rituximab,
splenectomy and stem cells transplantation are proposed [44, 45, 48]. Among our 3 infants with
ALPS, the resistance to steroid was noted in all; moreover, effect of MMF was partial and short
lasting. The best clinical results were obtained with sirolimus, used in children under one year
of age. All our patients were transplanted successfully with matched HSC from unrelated
donors (in 2 infants) and related donor (father) in one boy. The clinical course and therapy
results in these infants with severe symptoms of ALPS are shown in Table 3 [47].
Symptom/patients D.G. Boy Z.A. Girl W.S. Boy
Family history of ALPS Age of
diagnosis Lymphadenopathy
Splenomegaly
No 20 months
Present
megaspleen
Father – mild form
12 days of life
Present
Present
No
12 months
Present
megaspleen
Autoimmunity:
Thrombocytopenia
Haemolytic anaemia
Allergy:
Severe
Mild
Bronchial asthma
Severe
Severe
No
Mild
No
No
Therapy:
Steroids
High dose IVIG
Other – sirolimus
HSCT:
Donor
Course of transplant
Transient effect
Good effect
Related
Without complications
Resistance
No effect
Good effect
Unrelated
Loss of chimerism
Second transplant
Transient effect
Good effect
Unrelated
Loss of chimerism
Second transplant
Laboratory data:
Platelets (/ul) before and
after sirolimus
Leukocytes (/ul) before
after sirolimus
Hemoglobin (g/l) before
after sirolimus
DNT (CD3+/CD4-/CD8-)
(%) before
after sirolimus
53 000
145 000
2 900
10 500
97
111
31
9
67 000
159 000
22 100
7 200
67
96
26
8
86 000
314 000
11 100
5 600
73
123
22
2
Table 3. Infants with ALPS – clinical course and therapy results of our patients [acc.47]
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3. Pathogenesis of autoimmunity in humoral immunodeficiency
3.1. Role of autoantibodies
Autoantibodies are produced in the same way, like antibodies to pathogens and vaccine
antigens, by B-1 subpopulation of B lymphocytes and plasma cells. The main production is
localised in lymph nodes and bone marrow. Autoantigens originate from cells and tissues, so
the structure of cell surface (e.g. determinants, receptors present on cell), products of cell
(enzymes, hormones, pro-hormones, cytokines and other) and particles released after cell
death have become recognised antigens. Autoantibodies against DNA result from circulation
of nucleosomes containing DNA. The persistence of small population of self-reacting T and B
lymphocytes in thymus and bone marrow in physiology is responsible for physiological
presence of autoantibodies at low level. The increased occurrence and increasing amount of
autoantibodies with age, suggest the presence of this small population of self-reactive lym‐
phocytes during the entire lives of healthy people [49].
The inducing factor of autoantibodies production is not known to date, so different views are
postulated, e.g. chronic inflammation, molecular mimicry with microbial antigens, aberrant
expression of HLA-DR on cell surface (facilitating factor for immune response) as triggering
signal. However, in diseases like lupus with intracellular autoantigen, this hypothesis is not
very suitable. Perhaps the release of cytoplasmic organelles by dying cells and formation of
nucleosomes containing pure DNA, induce production of antibodies against them. The
antibodies’ pattern (e.g. against histones, centromers, centriols, nucleoli, Golgi apparatus,
mitochondria, peroxidase, specific proteins: Scl-70, RNP) is typical for particular diseases, but
the association between autoantibodies’ pattern and clinical features is far from explained [49].
The high level of autoantibodies present in serum is, in general view, associated with damage
of target cells, tissues or organs, followed by occurrence of clinical symptoms. The reaction of
antibodies with antigen forms immune complexes which circulate in serum and/or produce
deposits in capillary vessels, in the tissue expressing the autoantigen. With time, injury of tissue
is enough for clinical onset of disease. These immune complexes bind the complement and
activate its cascade, stimulating the production of pro-inflammatory cytokines, chemotactic
factors for infiltrating cells. This stimulation and hyper activation of immunocompetent cells
support the permanent synthesis of autoantibodies and amplification of chronic inflammation
(self-perpetuating inflammatory process). The antibodies play important role in the pathome‐
chanism of clinical symptoms in autoimmune diseases, though, not in all of them. Although,
the precise role of autoantibodies is unknown, their persistent production suggests the
participation in pathomechanism of disease. For example, the anti-transglutaminase antibod‐
ies present in celiac disease are associated with reduction of intestinal epithelial cells endocy‐
tosis, differentiation and proliferation, which results in decreased function of intestinal/
epithelial barrier. In histology of mucous membrane in untreated celiac disease, the epithelium
tends to blister or totally detach from the basement membrane, possibly the effect of inhibition
of epithelial cells adhesion caused by antibodies [50]. On the other hand, the role of autoanti‐
bodies in pathomechanisms of tissue damage in inflammatory bowel diseases (IBD – Leś‐
niowski-Crohn’s disease and ulcerative colitis) is not fully described [51-53].
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3.2. Production of autoantibodies in immunodeficiency
The serological diagnosis of autoimmune diseases is based on autoantibodies circulating in
the serum, as a marker of this process and presence of tissue deposits containing autoanti‐
bodies and complement. In CVID, the production of specific antibodies including autoanti‐
bodies is low, due to immune system dysfunction. Moreover, in CVID the deficiency of IgA is
frequent, so there is lack of antibodies in this immunoglobulin class. The histology of affected
tissues, in patients without PIDs, is typical and well known. In this group of patients, as an
effect of immunoglobulins and cells deficiency, the histology of affected tissue by autoimmune
process is different. B-cell deficiency and disturbances in maturation (e.g. memory cell
decrease, low number of plasma cells) are probable causes of different histology of intestine
in IBD present in CVID patients [8, 54]. In biopsy of jejunum mucous in celiac or Leśniowski-
Crohn’s disease in CVID patients, the infiltrates contain T lymphocytes, almost exclusively,
with low number of B and plasma cells. To differentiate atypical histological pattern of intestine
infiltrates in CVID from typical histology of affected intestine in otherwise healthy patients,
the celiac disease and Leśniowski-Crohn’s disease are termed “celiac-like, ” and “Crohn-like”
for CVID patients [8, 55-57].
In IgAD patients with celiac disease, the production of antibodies to gliadin, endomysium and
tissue transglutaminase are preserved, but in IgG class. However, in some IgAD patients, the
presence and high level of anti-transglutaminase antibodies may be shown in IgA, despite lack
of IgA in serum (assayed with nephelometry). In these cases, the trace level of IgA in serum is
enough to show antibodies to tissue transglutaminase, but with high sensitivity technique (e.g.
ELISA). The histology of jejunum in IgAD patients is typical for celiac disease and similar to
observed in children without IgAD. In some IgAD patients, serological diagnosis of celiac
disease is suggested by other symptoms then directly associated with digestive tract (e.g.
underweight, inhibition of growth, afts, low iron level). Moreover, in these patients, the typical
changes of structure of jejunum villi may be absent (Marsh type 0). The time of introduction
of restricted gluten-free diet (GFD) is a matter of discussion, depending on clinical symptoms
from digestive tract, occurrence or progress of other symptoms, e.g. growth inhibition, loss of
weight. It is obvious that in IgAD, plasma cells producing IgA are missing, although, total
number of plasma cells is normal within infiltrates in jejunum. The GFD is effective in resolving
the clinical symptoms of celiac disease in majority of IgAD patients [25, 55].
In CVID, the serological diagnosis of celiac disease is more difficult and doubtful, due to low
production of antibodies both in IgG and IgA due to IgA deficiency in CVID [7-8, 55]. However,
the permanent stimulation with autoantigens and antigens (e.g. gliadin) is enough to induce
and to support the synthesis of antibodies/autoantibodies, overcoming the impaired function
of immune system. The level of autoantibodies in serum is often lower than in patients without
immune deficiency [54, 56-58]. In our observations, these antibodies present in low level were
clinically significant, so, they should be considered in CVID patients as marker of celiac disease.
3.3. Role of T regulatory cells
The T regulatory subpopulation of T lymphocytes (Treg, CD4+/CD25+/FoxP3+) consists of the
natural Treg from thymus and inducible Treg (iTreg), both involved in regulation of autoim‐
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mune reaction of immune system. Extensive studies have shown the role of Treg in monitoring
the immune response, especially, in control of hyperactivity leading to imbalance of immune
response to pathogens and self-perpetuating inflammation process. Treg cells are important
for regulation of the activity of mucous membrane associated lymphoid tissue of gastrointes‐
tinal and respiratory tracts [59-61]. The population of Treg lymphocytes in peripheral blood is
assayed with flow cytometry; Treg lymphocytes localised in the tissue and in inflammatory
infiltrates are detected with immunohistochemistry. The immunohistochemistry is a sensitive
method commonly used for analysis of the presence, proportion and characteristics of different
– not only Treg – cells, within inflammatory focuses in tissues, e.g. macrophages, T and B
lymphocytes, plasma cells. The data from many indicated the central role of this T lymphocytes
subpopulation in regulation of prolonged inflammatory process within mucous membrane of
gastrointestinal and respiratory tracts, joints and other tissues. The analysis of Treg lympho‐
cytes number in Leśniowski-Crohn’s disease and ulcerative colitis (UC) showed increased
amount of these cells within lamina propria; whereas, the number of Treg in peripheral blood
was decreased as compared to healthy people. This study of Treg cells in biopsy of intestine
helped to classify the IBD patients into subgroups, based on relations between Treg number
within infiltrates, clinical symptoms and course of disease. It will create specific “biological
signature, ” unique to each patient, leading to individualisation of therapy (“patient tailored”)
with hope for more rational therapy targeting the specific intestinal inflammatory pathway
recognised in this patient [59, 62].
4. Autoimmune haematological syndromes
4.1. Thrombocytopenia acute and chronic
Thrombocytopenia associated with immunodeficiency presents two clinical forms – episodes
of acute thrombocytopenia alone or as a part of Evans syndrome, with normal number of
platelets in remission, and chronic thrombocytopenia, with number of platelets always below
normal level [63-65]. In ALPS and WAS, thrombocytopenia is one of the criteria of a particular
immunodeficiency type, so this symptom, in chronic form, is constantly present in all patients.
However, the chronic form of thrombocytopenia does not exclude the exacerbations with life-
threatening low numbers, or even absence of platelets. Therapy with platelets infusions, high
dose of immunoglobulins and other immunosuppressive drugs (e.g. steroids, mycophenolate
mofetil, sirolimus, classical drugs, rituximab) is effective; however, in majority of patients, this
effect is transient. The severe clinical course of ALPS and progressing symptoms of WAS (with
time) are indications for HSCT in these patients [40, 44, 45, 47, 48].
In our group of CVID patients with thrombocytopenia, all these forms (acute, chronic,
exacerbations of chronic form) were noted, without relation to time of CVID diagnosis and
duration. Moreover, in part of patients, thrombocytopenia was diagnosed prior to CVID onset
and established diagnosis. Regular substitution of immunoglobulins in replacing dose (0.4 –
0.6 g/kg b.w. intravenously) is not effective in control of platelets number in exacerbation of
chronic thrombocytopenia or prevention of acute thrombocytopenia episodes in CVID. The
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standard therapy of thrombocytopenia with steroids and high-dose immunoglobulins (1.0 -
2.0 g/kg b.w.) is required. Moreover, this immunoglobulins therapy is successful in majority
of CVID patients, despite regular substitution of immunoglobulins in replacing dose. After
infusion of immunoglobulins in high dose, the regular substitution is continued, supporting
the remission of thrombocytopenia. However, there are still problems in management of
thrombocytopenia in CVID – short effect of therapy for acute episodes, necessity of mainte‐
nance therapy in remission. Long-lasting remission, with normal number of platelets in CVID
patients, is similar to patients without CVID, when good results are obtained with high dose
of immunoglobulins and/or steroids therapy. However, in part of CVID patients, acute
thrombocytopenia showed tendency to chronicity. In chronic form of thrombocytopenia with
number of platelets below 100 000/ul, the regular substitution of immunoglobulins in replacing
dose seemed to stabilise platelets number, without need for additional therapy, e.g. steroids
or azathioprine. Clinical observations of our CVID patients with chronic thrombocytopenia
showed increase of platelets number only for few days after infusion of replacing dose
immunoglobulins, followed by low decrease during next 3 weeks, although, the platelets
number, in nadir, was still higher than in acute episodes of thrombocytopenia. This stable,
safety level of platelets, on regular substitution of immunoglobulins (replacing dose) without
additional therapy of thrombocytopenia, allows patients to live normally (Table 4) [66].
Patient number1 boy 2 boy 3 boy 4 girl 5 boy 6 boy 7 boy
Diagnosis:
CVID
thromboc.
6 years 14 years8 years 4
years
3 years 6 mths, 4
years 10 mths
12 years, 8
years
10 years 11
years
8 years, 7
years
5 years, 13 years
Main
symptoms of
CVID
Infections of
respiratory
tract,
lymphadeno-
pathy,
splenomegaly
Thromboc.
spleno-
megaly
Severe
thromboc.
lymphadeno-
pathy
splenomegaly
Thromboc.
leukopenia
Thromboc. Thromboc. Pneumonias
lymphadeno
pathy,
splenomegaly
Laboratory
data at
diagnosis of
CVID
Low level of
IgG IgA, low
number of T
cells, reverse
D4:CD8 ratio,
weak response
to vaccines
Low level of
IgG, IgA,
IgM, low
number of T,
B and NK
cells
Low number
of T cells, lack
of response
T cells to
stimulation,
low level
of IgG
Low level of
IgG, IgA and
IgM, low
number of T,
B and NK
cells
Low level of
IgG
Low level
of IgG,
IgA,
Low level of IgG,
IgM, lack of IgA,
leukopenia, weak
response to
vaccines
Other
symptoms
Mild
leukopenia
leukopenia Severe
haemolytic
anaemia
Severe
leukopenia
no No Agenesis of
kidney, LIP, lung
fibrosis
(progression),
bronchiectases
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Patient number1 boy 2 boy 3 boy 4 girl 5 boy 6 boy 7 boy
Dose (g/kg
b.w. /month)
and response to
IgG
0.43-0.38 good,
no infections
0.36 good 0.35 – 0.42 good 0.35 – 0.45
weak
(increase of
platelets 2-3
days)
0.38 – 0.3
good
0.4 – 0.35
good
0.45 – 0.3 weak
(low level of IgG)
Complications
of therapy
Adverse
reaction to
IVIG
Severe
osteoporosis,
overweight,
delay of puberty
Other therapies Steroids before
IVIG
Steroids,
azathioprine
(lung fibrosis)
progress
Present status SCIG IVIG No substitution,
hematology
care
IVIG,
hematology
care
No
substitution,
no
symptoms
No
substitu-
tion no
symptoms
SCIG, lungs and
kidney
insufficiency,
splenomegaly
Therapy of
thrombocyto-
penia
steroids
(pulses)
IVIG 1.0g/kg
b.w. steroids,
azathioprine
steroids,
azathioprine,
IVIG 1.0 g/kg
b.w.
steroids steroids,
IVIG 1.0
g/kg b.w.
steroids steroids
Complications,
other symptom
No No Severe
haemolytic
anaemia (Evans
syndrome)
Diabetes,
severe
overweight
No No
Lowest number
of platelets (/ul)
28 000 0 0 0 27 000 20 000 37 000
Number of
platelets at
IVIG beginning
253 000 156 000 133 000 15 000 44 000 87 000 126 000
Mean number
of platelets
during IVIG
(/uL)(range)
149 100
(120 000-
196 000)
166 000
(141 000-
198 000)
131 000
(97 000-
154 000)
51 460
(18 000-
68 000)
113 500
(56 000-
154 000)
172 400
(99 000-
264 000)
112 700
(86 000-133 000)
Number and
therapy of
thromboc.
exacerbations
1
IVIG 1.0 g/kg
b.w. steroids
3 (1 severe)
Steroids,
platelets,
erythrocytes
and plasma
4 IVIG 1.0
g/kg b.w.
1 (severe)
Steroids,
splenectomy
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Patient number1 boy 2 boy 3 boy 4 girl 5 boy 6 boy 7 boy
transfusions,
plasmapheresis
IVIG (1.0g/kg
b.w.)
Time of
observation
12 years 2 years 7 years 4 years 5 years 4 years 11 years
Table 4. Characteristics and course of CVID in patients with thrombocytopenia (thromboc.) [acc.66]
The regular substitution of immunoglobulins in replacing dose not only supplements specific
antibodies, but also stimulates maturation of dendritic cells. This activity of immunoglobulins
used in substitution was noted in XLA patients with defective dendritic cells phenotype.
Similarly, defective phenotype of dendritic cells was found in CVID patients. The dendritic
cells play a critical role in predisposition to pathological conditions, e.g. bacterial infections
due to impaired antigen presentation and initiating the immune response, induction of
autoimmunity process. Stimulation of dendritic cell maturation might be preventing the
development of autoimmunity associated with defective function of these cells in immuno‐
deficiency patients. It is believed, that regular substitution of immunoglobulins, even in
replacing dose, restores the normal phenotypes of dendritic cells and their proper function [67].
In CVID patients demonstrating refractory thrombocytopenia, recurrent episodes of exacer‐
bations or chronic thrombocytopenia, second-line therapy with immunosuppressive drugs
like azathioprine, vincristine, cyclophosphamide and splenectomy is used [63-65]. Moreover,
in CVID patients, refractory thrombocytopenia seemed to be more frequent, followed with
higher ratio of indications for splenectomy, than in otherwise healthy children. Splenectomy
is effective and safe in CVID patients, without higher risk of severe infections due to immu‐
nodeficiency. Moreover, the long-lasting results are similar to patients without immunodefi‐
ciency [64]. Another therapeutic option for severe thrombocytopenia in CVID patients with
normal number of B cells is monoclonal antibody against CD20 (e.g. rituximab) for elimination
of B lymphocytes [68, 69]. For these patients with CVID, the risk for severe infections seemed
to be higher and substitution of immunoglobulins in replacing dose should be continued every
month, without decreasing the dose and/or pause, e.g. for holidays [11, 63, 64, 69]. Thrombo‐
cytopenia in CVID patients is considered as unpredictable autoimmune symptom, so a very
careful clinical and laboratory monitoring is required.
4.2. Neutropenia/leukopenia, haemolytic anaemia
Neutropenia is very often associated with hyper IgM syndrome (especially in CD40L – X linked
and CD40 deficiency type), leading to severe clinical course of infections, e.g. sinusitis, otitis,
osteomyelitis [16, 18, 70]. In some patients, recurrent and persistent ulcers of the mucous
membrane, e.g. palate, oral cavity, are noted in episodes of deep neutropenia. The symptomatic
therapy is based on antibiotics/sulphonamides in prolonged course, granulocyte colony
stimulating factor (G-CSF) and immunoglobulin substitution with good effect, but not in all
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patients. For hyper IgM patients with severe clinical course, resistance to therapy and episodes
of severe bacterial or fungal infections, HSCT is recommended as curative therapy.
In CVID, leukopenia and/or neutropenia, mainly in mild form, is frequently noted. Within our
group of CVID children, leukopenia was observed in few patients, but was persistent and
refractory to immunoglobulins substitution and without relation to IgG level. However, due
to mild clinical form, additional therapy (e.g. G-CSF for neutropenia) is required in singular
cases only [71].
It is noted that haemolytic anaemia presents severe clinical symptoms in patients with CVID,
hyper IgM, Wiskott-Aldrich syndrome and ALPS. In ALPS, the clinical course of haemolytic
anaemia may be life-threatening due to severity and high frequency of episodes. Moreover,
these episodes of severe anaemia cause complications, e.g. high level of iron, hepatospleno‐
megaly (megaspleen), poor general condition of patients. This severe clinical course of ALPS
and resistance to steroids, immunoglobulins and immunosuppression therapy are an indica‐
tion for HSCT as life-saving procedure [47]. Moreover, for patients with milder course of ALPS,
symptomatic therapy with good response and careful monitoring of blood parameter are
satisfactory.
5. Involvement of the gastrointestinal tract in primary immunodeficiency
5.1. Celiac disease
Celiac disease diagnosed as latent, silent or atypical form, in children older than infants,
comprises about 80% of total number of celiac paediatric patients. The clinical symptoms in
atypical form of disease are discrete or unspecific, so the diagnosis is often delayed. Moreover,
there have been more than 200 symptoms reported in association with gluten sensitivity, which
does not facilitate establishing proper, early diagnosis [72]. Low levels of iron, resistant to oral
therapy, vitamins (e.g. vit. D), calcium, zinc and other minerals deficiency are symptoms
suggesting jejunum dysfunction (malabsorption), typical for celiac disease in children and
teenagers [73]. The clinical symptoms of celiac disease may be unspecific (e.g. underweight,
inhibition of growth, afts), delicate and overlapping with symptoms characteristic of immu‐
nodeficiency (IgAD, CVID without IgA), like abdomen pain, episodes of diarrhoea, chronic
diarrhoea, food allergy [72, 73]. The co-existence of IgAD and celiac disease (frequency of celiac
disease within IgAD patients is 10–20 times higher than in healthy children) supported the
idea of the common genetic background for these two diseases. The study indicated the
ancestral haplotype HLA-A1, Cw7, B8, DR3, DQ2 as important for this association of two
diseases. However, the frequency of celiac disease within IgAD population is still lower, than
expected, based on common genetic background, so this hypothesis remains without confir‐
mation [73]. The other explanation is based on persistent stimulation of immune system
associated with mucous membrane, by gluten and gliadin in absence of IgA, which leads to
the damage of jejunum and onset of clinical symptoms. Stimulation of immune system,
including B lymphocytes, was represented by increased expression of B lymphocyte stimulator
(BLyS) and a proliferation-inducing ligand (APRIL) in patients with IgAD and celiac disease,
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although, the difference between IgAD patient with and without celiac disease was non-
significant. Stimulation of B lymphocytes (increased APRIL level) might be important for
compensatory local production of IgG and IgM [74]. The number of T lymphocytes TCR γ/δ
infiltrating epithelial cells (IEL) was higher in IgAD patients than in healthy people, but lower
than number of IEL TCR γ/δ noted in IgAD with co-existent celiac disease [75].
5.2. Leśniowski-Crohn’s disease and ulcerative colitis
Chronic diarrhoea as typical clinical symptom of gastrointestinal involvement is seen in a wide
range of adult patients (10–50%) with CVID [8, 27, 55, 76]. In children with CVID and IgAD,
chronic diarrhoea is much less frequent, but clinical data are based on relatively small number
of patients. In IgAD children, the IBD was noted sporadically, with clinical course similar to
children without IgAD. In CVID patients, the IBD remains a significant problem for 19–32%
of patients [27]. In adults with Leśniowski-Crohn’s disease and CVID, besides typical changes
of intestine wall and surface, the formation of granulomas is noted. Furthermore, the substi‐
tution of immunoglobulins does not inhibit and/or reverse the symptoms of chronic colitis [77,
78]. A variety of explanations are proposed, but the hypothesis that IgG from immunoglobulin
preparations are not able to reach the epithelium of intestine, even intact, seems to be inter‐
esting. It might explain higher incidence of small bowel inflammation, with severe and
progressing course, especially in patients with CVID without IgA, treated with regular
immunoglobulins substitution in replacing dose. The other possible mechanisms explaining
the differences in Leśniowski-Crohn’s course between CVID patients and healthy people are
associated with Treg defects, inflammation supported by activated T lymphocytes, and
different list of cytokines produced locally within intestine wall [77]. The role of T lymphocytes
is postulated based on different histology of infiltrates within wall of small intestine in CVID.
The main difference in proportion between T and B lymphocytes within infiltrates is lack of
plasmocytes. The remaining phenomena, e.g. the villi flattening, increased number of IEL and
lymphocytes in lamina propria, and increased epithelial apoptosis, were observed in CVID
patients similar to patients without CVID [27, 77, 78]. The distinct pathway of inflammation
in CVID depends also on cytokine profile, when the production of IL-23, IL-17 and TNF is
lower in CVID than in Leśniowski-Crohn’s patients without CVID [77].
5.3. Autoimmune hepatitis
The exact aetiology of autoimmune hepatitis, similar to other autoimmune diseases, is
unknown, but viral infections, especially hepatotropic, and drugs may be the trigger. In
etiopathology, the immunological mechanisms involved the function of Treg cells, IgA defence
against gastrointestinal pathogens, including viruses [79, 80]. In adult patients with CVID,
autoimmune chronic hepatitis is noted in about 10% [78]. The study of autoimmune paediatric
liver disease showed association between IgAD and autoimmune hepatitis type 2 with slower
progression to cirrhosis than in hepatitis type 1 [81]. This association might facilitate autoim‐
mune hepatitis in patients with IgAD and CVID with low IgA. In patients with hyper IgM
syndrome (mainly X-linked), typical liver involvement is associated with Cryptosporidium
parvum infection. After gastroenteritis, this pathogen infected the epithelium of bile vessels
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system. In this immune deficiency, T lymphocytes are enable to destroy the infected cells,
which results in persistence of pathogen, chronic inflammation, development of sclerosing
cholangitis and chronic hepatitis followed by liver failure [7, 11, 78]. One of our patients with
X-linked hyper IgM syndrome showed clinical symptoms of sclerosing cholangitis and
progressing liver insufficiency. After successful HSCT from MHC-matched healthy sister, the
symptoms of cholangitis and cryptosporidiasis resolved. Now, he is free from immunodefi‐
ciency and liver symptoms and living normally [personal communication].
5.4. Other autoimmune diseases in patients with immunodeficiency
In adult patients diagnosed with CVID, the autoimmunity presented a different pattern as
compared to children. Rheumatoid arthritis, systemic lupus erythematodes are more frequent
than gastrointestinal tract disease; however, the haematologic symptoms are equally frequent
in children and adult CVID patients [27, 82]. Rheumatoid arthritis is noted in hyper IgM
patients and, what seemed unusual, in X-linked agammaglobulinemia [83, 84]. The explana‐
tion of this phenomenon is based on detection of small population of immature B cells in
peripheral blood. These B cells are often autoreactive, which suggests that the central and
peripheral mechanisms of tolerance have failed [11]. One of our boys with XLA developed
eosinophilic fasciitis of right crus, with poor response to immunoglobulins in high dose and
non-steroidal anti-inflammatory drugs. Now, the improvement was obtained with steroids in
high dose (intravenous pulses), followed with steroids in maintenance dose and MTX in
prolonged therapy. However, immunosuppression with MTX was complicated with pneu‐
monia (twice) due to XLA, so MTX was changed to mycophenolate mofetil with good response
and hope for fewer side effects and better tolerance by immune system. The partial remission
(mild symptoms without pain) obtained with MTX continues and, now, the boy is attending
school normally, extra effort being the only limitation.
6. Diagnosis and management of primary immunodeficiency with
autoimmunity
6.1. Substitution of immunoglobulins
The main goal of regular substitution of immunoglobulin IgG (intravenous or subcutaneous)
in X-linked agammaglobulinemia, hyper IgM syndrome and CVID is supply of the specific
antibodies. The immunoglobulins, mainly IgG with trace of IgA witout IgM, are separated and
purified from serum of healthy blood donors. The antibodies, important for immunodeficient
patients, are active against common pathogens and vaccines antigens, so they are able to
prevent infections, but with spectrum of common pathogens. The regular substitution of
immunoglobulins should be provided according to standard indications for patients with low
but basic levels of IgG in serum. The substitution for XLA, hyper IgM patients, in first moment
after diagnosis is individualised depending on clinical state and present infections. For patient
without infections, but with IgG level below detection, intravenous substitution (IVIG) should
be introduced in higher dose (e.g. 0.75 g/kg b.w.) in 2 weeks period, up to the safety level of
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IgG in patient’s serum (5.0–5.5 g/l). The standard schedule of IVIG is based on half-life of IgG
(21–24 days), so the dose 0.4– 0.6 g/kg b.w. is regularly infused every month. The clinical
observations of effects of immunoglobulins substitution showed the 6–8 months period as time
required for patient’s stabilisation (“steady state”). However, in some CVID patients, obtained
IgG level within normal value for age is not enough to prevent recurrent infections. For these
patients, the “through level” is used as indication for individualised dose of immunoglobulins
substitution [27, 39, 77, 85-87]. The modifications of IVIG includes shorter time between the
infusion or higher level in singular infusion, due to bacterial infections, wound healing or other
causes leading to overconsumption of immunoglobulins. In XLA without infections, the lower
dose (0.2–0.3 g/kg b.w.) in longer period (e.g. 6 weeks) may be used. Moreover, adults with
complications like chronic lung disease, chronic sinusitis or gastrointestinal disease may
require the individual schedule of substitution (“patient-tailored therapy”). These modifica‐
tions are based not only on clinical patient status, but on careful, precise monitoring of IgG
level [27]. The immunoglobulins offered as substitution should prevent the occurrence of
infections, at least, to decrease their frequency, soften the clinical course and improve the
response to therapy. Moreover, the regular substitution of IgG in replacing dose, seemed to
be effective (stabilising) in chronic thrombocytopenia and chronic neutropenia in some
patients with this type of autoimmunity [77]. This effect is probably associated with anti-
inflammatory activity of IgG, even in replacing dose, although, the precise mechanisms are
not described. One interesting observation showed the activation of monocytes subpopulation
in patients with CVID after immunoglobulins infusion in replacing dose [88]. It might be that
the regular, long-term continued substitution may lead to accumulation of small, repeated
effects of IgG, resembling the anti-inflammatory activity of this immunoglobulin in low
replacing dose. The mechanisms responsible for anti-inflammatory activity of IgG prepara‐
tions used in high dose of immunoglobulins (1.0–2.0 g/kg b.w.) for autoimmune diseases
therapy (e.g. acute thrombocytopenia, Kawasaki disease, Guillain-Barre syndrome, myasthe‐
nia crisis) are well defined and mainly based on regulatory activity [27, 86, 89].
The adverse reactions of IVIG may occur immediately, during the infusion or after, up to 4
days. The symptoms of adverse reactions are mild or severe, including anaphylactic shock as
most severe reaction, occurring often very quickly, after few drops of immunglobulins’
solution. Fever, chills, pain (headache, abdominal pain) and cough are noted in children as
mild symptoms resolved with appropriate symptomatic therapy. The late, severe reactions are
the consequence of immunoglobulins distribution into tissues, especially into central nervous
system. Severe and progressive headache, vomiting, disturbances of vision, speech and
balance are neurological symptoms typical for this reaction. Intensive hydration (decrease of
IgG level, filling the vessels) and steroids (anti-oedematic activity) given intravenously are
effective as therapy [77, 90, 91]. In case of severe adverse reactions, the subcutaneous way of
immunoglobulins substitution (SCIG) is recommended. The amount of immunoglobulins
given monthly is divided in four portions (0.1– 0.2 g/kg b.w. per week), administered with
special pump in children or with syringe only (“rapid push”) in adults. The effectiveness of
SCIG is similar to IVIG, but the adverse reactions are very rare and limited to the place of
injection. SCIG is a form of home therapy, very comfortable for patients, offering independence
from hospital. In XLA, CVID diagnosed in adults, hyper IgM syndrome, the regular substitu‐
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tion of immunoglobulins is for life, so the SCIG form of immunoglobulins substitution is
preferred for these patients avoiding the pain associated with poor vein access after years of
IVIG. The exception from indication for “substitution for life” is patients with X-linked hyper
IgM syndrome treated with HSCT [92-94]. In children with CVID, the developing immune
system gives the opportunity to hang off the substitution after reaching the stable, normal level
of IgG, low frequency of infections with good response to therapy, resembling the immune
system maturation.
6.2. Symptomatic therapy and prophylaxis of infections
In part of children with CVID, the effect of regular immunoglobulins substitution (IVIG or
SCIG) is weak and infections, mainly in respiratory tract, are still present. With time, in some
of these patients, the lymphocytic interstitial pneumonia (LIP, or GLILD – granulomatous
lymphocytic insterstitial lung disease), chronic sinusitis and bronchiectases develop, pro‐
gressing lung fibrosis and persistent leukopenia (neutropenia) are noted, so prophylaxis with
antibiotics is recommended. The 3–4 months’ period of antibiotics or time-to-prime in
prophylactic dose is commonly used as effective schedule of supportive therapy, improving
clinical status of patients. However, the therapy with antibiotics is still a matter of discussion
and different approaches to this therapy are suggested depending on clinical centre and
severity of patients’ symptoms. The specific and unique recommendation for antibiotics
prophylaxis is aimed at prevention of endocarditis following invasive procedures in immu‐
nodeficient patients [39]. In our clinical management of more than 200 immunodeficient
patients, such complication was not observed, but because of the severity of this symptom,
prophylaxis should be considered.
6.3. Monitoring and therapy of co-existent autoimmunity
Therapy of common autoimmune diseases, e.g. thrombocytopenia, neutropenia, haemolytic
anaemia, in patients with immunodeficiency is based on standard therapy of such symptoms;
the use of immunoglobulins in high dose, steroids, immunosuppression with methrotrexate,
vincristine, azatioprine, but special therapy is required for some of immunodeficient patients.
In ALPS, the use of sirolimus is suggested, as possibility to induce apoptosis, helping in
elimination of double-negative T lymphocytes. Sirolimus is preferentially used in these
patients for resolving symptoms (e.g. lymphadenopathy, splenomegaly) and diminish the
severity of clinical course. The expected effect of sirolimus is to diminish the spleen volume
(megaspleen), one of most danger symptom in children with ALPS [44-47].
The therapeutic approach to immunodeficient patients with Leśniowski-Crohn’s disease is
generally similar to therapy of patients without immunodeficiency; although, inflammation
process in CVID might be resistant to therapy. In these patients, the process of intestine
inflammation is active despite immunosuppression (e.g. azathioprine, cyclosporine) used as
second line of therapy, after systemic steroids, budesonite and anti- inflammatory non-
steroidal drugs without remission. Therapy with the monoclonal antibodies against TNF
(infliximab, etanercept) is effective in inductions the remission in patients with immunodefi‐
ciency, similar to patients without immunodeficiency. However, CVID patients are more
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prone to infections during such therapy, so very careful monitoring of this group of patients
is recommended, not only for bacterial, but fungal and viral infections, due to defects of T
lymphocyte function [8].
The frequency of UC in CVID and IgAD patients is not known, but it seems that in children it
is even less frequent than in adult CVID and IgAD patients. In a large group of CVID patients
(248 children and adults), UC was noted in 7 patients; however, the unspecific significant
malabsorption symptoms were observed in other10 patients [26]. It shows the problem of
overlapping symptoms, difficulties in establishing the precise diagnosis and requirement for
wide differential diagnostic procedures performed in these patients [26].
7. Progress in therapy of autoimmunity
7.1. Indications for monoclonal antibodies
Monoclonal antibodies are used for elimination of target cell population, cytokine or blocking
of determinants on cell surface. Humoral immune deficiency is based on B-cell intrinsic
deficiency and disturbances of B-cell ontogeny. Autoimmunity in patients with very low
number of B lymphocytes is associated with relatively high number of autoreactive B cells
within this small B-cell population. Following this hypothesis of autoimmunity in humoral
immunodeficiency, the therapy with monoclonal antibodies against B lymphocytes seems to
be logical and reasonable. Use of rituximab (monoclonal antibody against CD20 determinant
restricted to mature B lymphocytes) in autoimmune cytopenias in CVID, ALPS and hyper IgM
syndrome (as alternative to HSCT) was successful [19, 44, 45, 95].
The therapy of autoimmune diseases characterised by chronic inflammatory process (SLE,
rheumatoid arthritis, IBD) with important role of cytokines and T lymphocytes includes
monoclonal antibodies against cytokines (TNF), IL-2 receptor on T lymphocytes (CD25 as
activation marker) and others. Within CVID patients, celiac disease is often refractory to GFD
(RCD), leading to malabsorption syndrome and severe clinical conditions [11, 27, 96, 97], which
suggests different mechanism present in these patients. Careful observation and studies
showed different forms: type I with T lymphocytes with normal phenotype (expression of CD3
and CD8 determinants, normal polyclonal T-cell receptor (TCR) arrangement) and type II with
aberrant T lymphocyte phenotype, intracellular presence of CD3, monoclonal TCR rearrange‐
ment [8, 96, 98]. Type II of progressing celiac disease in spite of GFD and some cases of Crohn-
like disease are associated with poor prognosis with increased mortality, due to progressing
malabsorption syndrome and T-cell lymphoma in reasonable number of such patients [77,
96]. After standard therapy without effect, the second-line therapy with immunosuppression
(azathioprine) and/or monoclonal antibodies against TNF (infliximab, etanercept, humira) is
required for patients with active, progressive disease [99].
7.2. Suppressive therapy
The first line of immunosuppressive therapy in patients with or without immune deficiency
includes steroids, in individual doses, for all autoimmune symptoms and diseases. For
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cytopenias, especially thrombocytopenia, the schedule with high doses of steroids given
intravenously every month (“pulses”) is often used to increase the number of platelets. Chronic
thrombocytopenia is controlled with maintenance dose of steroids, but the side effects of
steroids are the main limitation for this therapy. The second-line therapy includes typical
immunosuppressants, e.g. azathioprine, metotrexate, vincristine, cyclophophamide, cyclo‐
sporine A. In ALPS, sirolimus and mycophenolate mofetil are suggested, with good clinical
response in majority of patients. Moreover, this therapy is well tolerated, without severe side
effects, even in infants and babies with ALPS. Regular substitution of immunoglobulins
(recommended in intravenous form) is important to diminish the risk of infections associated
with prolonged immunosuppression [7, 77, 78, 95].
7.3. Indications for haematopoietic stem cells transplantation (HSCT)
Historically, the first group of patients who underwent HSCT as a life-saving and curative
therapy were newborn babies diagnosed with SCID. The following group of patients transplant‐
ed with HSCT were children with X-linked immunodeficiency, e.g. hyper IgM syndrome, WAS,
chronic granulomatous diseases (CGD) [100-104]. The increasing number of children cured
from SCID, improvement of transplantation procedure (low risk factor) and post-transplant
care, is encouraging transplantologists and immunologists to offer this therapy for patients with
other types of primary immunodeficiency. Now, patients with ALPS, X-linked lymphoprolifer‐
ative diseases, haemophagocytic lymphohistiocytosis are transplanted in increasing numbers
[102]. Successful HSCT in SCID patients, after matched donor transplant, in Europe is 90%
survival; non-SCID immunodeficiency patients – about 80%, which means real, great prog‐
ress in treatment of patients with severe clinical forms of immunodeficiency [101].
The hyper IgM syndrome, ALPS, Wiskott-Aldrich syndrome may represent mild clinical
course with satisfactory symptomatic therapy, so HSCT is not a first-line therapy. The
indications for HSCT in these patients are based on severe clinical course, progress of symp‐
toms associated with immunodeficiency leading to poor prognosis for life [47, 100-104]. The
symptomatic therapy in these syndromes include steroids for severe autoimmunity symp‐
toms, regular substitution of immunoglobulins, antibiotics and antimycotic drugs as prophy‐
laxis, and treatment for existent bacterial, fungal and viral infections. This therapy is necessary
up to the time of HSCT, as good clinical state of patient decreases the risk of complications
after HSCT. The CVID with typical clinical course is not an indication for HSCT, due to
satisfactory effects of symptomatic therapy, much more save, than HSCT. However, in
individual cases with progressing, severe complications, like RCD, IBD, leading to malnutri‐
tion, this procedure is recommended [97]. Within our CVID children, HSCT was performed
with success in girl with severe malnutrition due to malabsorption in celiac disease resistant
to GFD. She was treated for few years with restricted GFD, antibiotics, steroids, anti-TNF
monoclonal antibodies, immunosuppression (cyclosporin A) without effect, so HSCT was the
life-saving procedure. HSCT was performed in our 3 patients (children below age of 3 years)
with severe course of ALPS, when therapy with steroids, immunoglobulins, mycophenolate
mofetil and sirolimus was without long-lasting remission and progression of the autoimmune
symptoms [47].
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8. Other problems
8.1. Granulomatous and lymphocytic interstitial lung disease (GLILD) – autoimmunity or
not
GLILD (former name – lymphoid interstitial pneumonia) is a rare clinical entity with unknown
aetiology and pathophysiology. The diffuse infiltration of lymphoid cells localised mainly in
the interstitial tissue is a typical histopathological feature. LIP is typically associated with
autoimmunity, e.g. Sjogren syndrome, autoimmune thyroid disease, SLE, but also with
immunodeficiency, mainly CVID and AIDS [105, 106]. LIP is noted in about 10% of CVID
patients, which could indicate the association between these clinical features. This type of
interstitial pneumonia is an independent factor of poor prognosis with negative impact on the
survival of patients due to lung fibrosis, followed by recurrent episodes of pneumonia with
infiltrations. Clinical symptoms of GLILD overlap with chronic bronchitis or bronchiectases,
signalled by prolonged cough. Moreover, the regular substitution of immunoglobulins, in
replacing dose, is not effective in prevention and resolving of these lung symptoms. Therapy
included prolonged steroids and/or immunosuppression (azathioprine, cyclophosphamide)
in individual combination, depending on patient immune system and clinical symptoms.
Prolonged therapy with steroid or immunosuppression is difficult in CVID patients, due to
increased risk of infections, potentiating of leukopenia/neutropenia and thrombocytopenia.
Among our patients with CVID, treated with regular substitution of immunoglobulins, LIP
was noted in 3 children. The clinical course of CVID was severe due to RCD in girl (later on
transplanted with HSCT), leukopenia (neutropenia) and thrombocytopenia in both boys.
Moreover, one of these boys diagnosed with LIP, demonstrated hepatomegaly, splenomegaly
and lymphadenopahty localised in lungs hilus and in mesenterium. Therapy of LIP included,
in first line, only steroids, followed by azathioprine (because of severe adverse reaction after
steroids and lack of effect), with good results in second boy. The resolving of LIP symptoms
was slow, taking 2–3 years of immunosuppressive therapy and regular substitution of
immunoglobulins in 0.5g/kg b.w. The frequency of infections during this therapy was not
higher, but the course of the few infections that occurred was prolonged, requiring antibiotic
therapy.
9. Conclusions and general remarks
Autoimmune diseases are a large group of heterogeneous diseases characterised by an
unpredictable course with variable response to immunosuppressive therapy, from very good
(long-lasting remission), to poor with progression of severe and life-threatening symptoms.
Autoimmune diseases in immunodeficiency syndromes can develop prior or after the onset
of immunodeficiency, during the regular substitution of immunoglobulins.
The management of patients with autoimmunity associated with immunodeficiency is more
difficult than patients without immunodeficiency due to various reasons: the production of
autoantibodies, the generally used marker of autoimmunity, is weaker in immunodeficiency;
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the clinical symptoms may overlap with basic symptoms of immunodeficiency; the response
to therapy is often poorer than in patients without immunodeficiency. The level of autoanti‐
bodies, below limit of positive results, due to immunodeficiency, should be considered as
significant for diagnosis of autoimmune disease in PID. The interpretation of laboratory results
in these patients need very careful and different attitude than usual. The resistance to therapy,
severe, and progressing symptoms of autoimmunity, as complication of immunodeficiency
(e.g. CVID, ALPS) are the indications for HSCT as life-saving procedure.
Acknowledgements
I would like to thank our immunologists’ team (Prof. Danuta Kowalczyk, Prof Maciej Siedlar,
Dr Anna Szaflarska, Dr Anita Błaut-Szlósarczyk, Dr Katarzyna Zwonarz) for taking care of
our patients with primary immunodeficiencies and transplantologists’ team (Prof. Assist,
Jolanta Goździk, Prof Assist. Szymon Skoczeń, Dr. Aleksandra Krasowska-Kwiecień, Dr
Agnieszka Dłużniewska) for closed cooperation and help in saving our patients’ life with
HSCT procedure.
Author details
Anna Pituch-Noworolska
Address all correspondence to: mipituch@cyf-kr.edu.pl
Department of Clinical Immunology, Polish-American Institute of Pediatrics, Jagiellonian
University, Medical College, Kraków, Poland
References
[1] Al-Herz W, Bousfiha A, Casanova J-L, Chapel H, Conley ME, Cunningham-Rundles
Ch, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarstrom L, Nonoyama S, Nota‐
ranghelo LD, Ochs HD, Puck JM, Roifman ChM, Seger R, Tang MLK (2011) Primary
immunodeficiency diseases: an update on the classification from the International
Union of Immunological Societies Expert Committee for primary immunodeficiency.
Front Immunol. 2; art. 54.
[2] Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunnigham-Rundles Ch,
Etzioni A, Fischer A, Franco JL, Geha RS, Hammastrom L, Nonoyama S, Ochs HD,
Roifman ChM, Seger R, Tang MLK, Puck JM, Chapel H, Notarangelo LD, Casanova
J-L (2013) A phenotypic approach for IUIS PID classification and diagnosis: guide‐
lines for clinicians of the bedside. J Clin Immunol. 33; 1078-1087.
Autoimmunity in Children with Primary Immunodeficiency – Diagnosis, Management and Therapy
http://dx.doi.org/10.5772/60882
87
[3] Chinen J, Notarangelo LD, Shearer WT (2013) Advances in basic and clinical immu‐
nology in 2012. J Allergy Clin Immunol. 131; 675-682.
[4] Coutinho A, Carneiro-Sampaio M (2008) Primary immunodeficiencies unravel criti‐
cal aspects of the pathophysiology of autoimmunity and of the genetic in autoim‐
mune disease. J Clin Immunol. 28; suppl.1, S4-S10.
[5] Notarangelo LD, Fischer A, Geha RS, Casanova J-L, Chapel H, Conley ME, Cunning‐
ham-Rundles Ch, Eztioni A, Hammarstrom L, Nonoyama S, Ochs HD, Puck J, Roif‐
man Ch, Seger R, Wedgwood J (2009) Primary immunodeficiencies: 2009 update.J
Allergy Clin Immunol 124; 1161-1678.
[6] de Vries E, Driessen G (2011) Primary immunodeficiencies in children: a diagnostic
challenge. Eur J Pediatr 170; 169-177.
[7] Arkwright PD, Abinun M, Cant AJ (2002) Autoimmunity in human primary immu‐
nodeficiency diseases. Blood. 99; 2694-2702.
[8] Agarwal S, Cunningham-Rundles C (2009) Autoimmunity in common variable im‐
munodeficiency. Curr Allergy Asthma Rep. 9; 347-352.
[9] Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Moulliot G, Jaussaud R, Viallard
J-F, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E,
Jaccard A, Gardeur A, Theodorou I, Rabian C, Debre P (2008) Infections in 252 pa‐
tients with common variable immunodeficiency. Clin Infect Dis. 46; 1547-1554.
[10] Arason GJ, Jorgensen GH, Ludviksson BR (2010) Primary immunodeficiency and au‐
toimmunity. Scand J Immunol. 71; 317-328.
[11] Cunningham-Rundles Ch (2011) Autoimmunity in primary immune deficiency: tak‐
ing lessons from our patients. Clin Exp Immunol. 164: 6-11.
[12] Schroeder HW, Szymańska-Mroczek E (2013) Primary antibody deficiencies. In:
Fourth Edition Clinical Immunology. Eds: Rich RR, Fleicher TA, Shearer WT, Schroeder
HW, Frew AJ, Weyand CM. Elsevier. pp. 421-436.
[13] Bao Y, Zheng J, Han Ch, Jin J, Han H, Liu Y, Lau Y-L, Tu W, Cao X (2012) Tyrosine
kinase btk is required for NK cells activation. J Biol Chem. 287; 23769-23778.
[14] Pituch-Noworolska A, Zwonarz K, Błaut-Szlósarczyk A, Szaflarska A, Kowalczyk D,
Siedlar M (2013) T lymphocytes and NK cells in X-linked agammaglobulinemia.
Przegl Lek 70; 1048-1050.
[15] Ochs HD, Smith C (1996) X-linked agammaglobulinemia. Medicine (Baltimore) 75;
287-299.
[16] Notarangelo LD, Hayward AR (2000) X-linked immunodeficiency with hyper IgM
(XHIM). Clin Exp Immunol. 120; 399-405.
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases88
[17] Pituch-Noworolska A, Kowalczyk D, Macura-Biegun A, Szaflarska A (2007) The clin‐
ical features of hyper-IgM syndrome. Centr Eur J Immunol. 32; 105-112.
[18] Davies EG, Thrasher AJ (2010) Update on the hyper immunoglobulin M syndrome.
Brit J Haematol. 49; 167-180.
[19] Hennig Ch, Happle Ch, Hansen G (2011) “A bad wound may heal, but a bad name
can kill” – lessons learned from “hyper IgM syndrome”. J Allergy Clin Immunol. 128;
1380-1382.
[20] Aghamohammadi A, Cheragi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh
M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M (2009) IgA deficiency: correla‐
tion between clinical and immunological phenotypes. J Clin Immunol. 29; 130-136.
[21] Fried AJ, Bonilla FA (2009) Pathogenesis, diagnosis, and management of primary an‐
tibody deficiencies and infections. Clin Microbiol Rev. 22; 396-414.
[22] Yel L (2010) Selective IgA deficiency. J Clin Immunol. 30; 10-16
[23] Notarangelo LD (2009) Primary immunodeficiencies (PIDs) presenting with cytope‐
nias. Hematology Am Soc Hematol Educ Program. 139-144.
[24] Vale AM, Schroeder HW (2010) Clinical consequences of defects in B-cell develop‐
ment. J Allergy Clin Immunol. 125; 78-787.
[25] Jacob CMA, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC (2008) Auto‐
immunity in IgA deficiency. J Clin Immunol. 28; S56-S61.
[26] Cunningham-Rundles Ch, Bodian C (1999) Common variable immunodeficiency.
Clin Immunol. 92; 34-48.
[27] Cunningham-Rundles Ch (2010) How I treat common variable immune deficiency.
Blood. 116; 7-15.
[28] Chapel H, Cunningham-Rundles Ch (2009) Update in understanding common varia‐
ble immunodeficiency disorders (CVIDs) and the management of patients with these
conditions. Brit J Haematol. 145; 709-727.
[29] Glocker E, Ehl S, Grimbacher B (2007) Common variable immunodeficiency in chil‐
dren. Curr Opin Pediatr. 19; 685-692.
[30] Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T (2009)
Common variable immunodeficiency: 20-years experience at a single centre. Pediatr
Allergy Immunol. 20; 113-118.
[31] Urschel S, Kaykci L, Wintergerst U, Nothes G, Jansson A, Belochradsky BH (2009)
Common variable immunodeficiency disorders in children: delayed diagnosis de‐
spite typical clinical presentation. J Pediatr. 154; 888-894.
[32] Alachkar H, Taubenheim N, Haenay MR, Dyrandy A, Arkwright PD (2006) Memory
switched B cell percentage and not serum immunoglobulin concentration is associat‐
Autoimmunity in Children with Primary Immunodeficiency – Diagnosis, Management and Therapy
http://dx.doi.org/10.5772/60882
89
ed with clinical complications in children and adults with specific antibody deficien‐
cy and common variable immunodeficiency. Clin Immunol. 120; 310-318.
[33] Huck K, Feyen O, Ghost S, Beltz K, Bellert S, Niehues T (2009) Memory B-cells in
healthy and antibody deficient children. Clin Immunol. 131; 50-59.
[34] Notarangelo LD (2010) Primary immunodeficiencies. J Allergy Clin Immunol. 125,
S182-S194.
[35] Wehr C, Kivioja T, Schmitt Ch, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M,
Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Guten‐
berger S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debre P, Jacobs R,
Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quin‐
ti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, War‐
natz K (2008) The EUROclass trial: defining subgroups in common variable
immunodeficiency. Blood. 111; 77-85.
[36] Warnatz K, Voll RE (2012) Pathogenesis of autoimmunity in common variable immu‐
nodeficiency. Front Immunol. 3; art. 210.
[37] Chase NM, Verbsky JW, Hintermeyer MK, Waukau AT, Casper JT, Singh S, Shahir
KS, Tisol WB, Nugent ML, Rao NR (2013) Use of combinations chemotherapy for
treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in pa‐
tients with common variable immunodeficiency. J Clin Immunol. 33; 30-39.
[38] Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz Kschulze I, Kindle G,
Kuijpers TW, van Beem RT, Guzman D, Workman S, Soler-Palacin P, De Gracia J,
Witte T, Schmidt RE, Lizman J, Hlavackova E, Thon V, Borte M, Borte S, Kumarar‐
atne D, Feighery C, Longhurst H, Helbert M, Szaflarska A, Sediva A, Belohradsky
BH, Jones A, Baumann U, Meyts I Kutukculer N, Wagstrom P, Galal NM, Roesler J,
Farmaki E, Zinovieva N, Ciznar P, Papadopoulou-Alataki E, Bienemann K, Velbri S,
Pnahloo Z, Grimbacher B for the European Society for Immunodeficiencies Registry
Working Party (2014): Clinical picture and treatment of 2212 patients with common
variable immunodeficiency. J Allergy Clin Immunol. 133: 1-11.
[39] Bethune CA, Spickett GP (2000) Common variable immunodeficiency. BioDrug. 13;
243-253.
[40] Catucci M, Castiello MC, Pala F, Bosticardo M, Villa A (2012) Autoimmunity in Wis‐
kott-Aldrich syndrome. Front Immunol. 3; art. 209.
[41] Park JY, Kob M, Prodeus AP, Rosen FS, Shcherbina A, Remold-O’Donnell E (2004)
Early deficit of lymphocytes in Wiskott-Aldrich syndrome: possible role of WASP in
human lymphocytes maturation. Clin Exp Immunol.136; 104-110.
[42] Ochs HD (1998) The Wiskott-Aldrich syndrome. Semin Hematol. 35; 332-345.
[43] Albert MH, Notarangelo LD, Ochs HD (2011) Clinical spectrum, pathophysiology
and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 18; 42-48
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases90
[44] Rao VK, Oliveira JB (2011) How I treat autoimmune lymphoproliferative syndrome.
Blood. 118; 5741-5751
[45] Teachey DT, Seif AE, Grupp SA (2009) Advances in management and understanding
of autoimmune lymphoproliferative syndrome (ALPS). Brit J Haematol. 148; 205-216.
[46] Kwon S-W, Procter J, Dale JK, Strus SE, Stroncek DF (2003) Neutrophil and platelets
antibodies in autoimmune lymphoproliferative syndrome. Vox Sanguinis. 85; 307-312.
[47] Szaflarska A, Pituch-Noworolska A, Błaut-Szlósarczyk A, Zwonarz K (2013) Autoim‐
mune lymphoproliferative syndrome (ALPS) in infants – indications and effects of si‐
rolimus therapy. First International Primary Immunodeficiency Congress,
7-8.11.2013 Estoril, Portugal.
[48] Rieux-Laucat F, Blanchere S, Danielan S, de Villartay JP, Oleastro M, Solary E, Bader-
Maunier B, Arkwright P, Pondare C, Bernaudin F, Chapel H, Nielsen S, Berrah M,
Fischer A, le Diest F (1999) Lymphoproliferative syndrome with autoimmunity.
Blood. 94; 2575-2582.
[49] Elkon K, Casali P (2008) Nature and function of autoantibodies. Nat Clin Pract Rheu‐
matol. 4; 491-498.
[50] Lindfors K, Kaukinen K (2012) Contribution of celiac disease autoantibodies to the
disease process. Expert Rev Clin Immunol. 8; 151-154.
[51] Ardesjo B, Portela-Gomez GM, Rorsman F, Gerdin E, Loof L, Grimelius L, Kampe O,
Ekwall O (2008) Immunoreactivity against goblet cells in patients with inflammatory
bowel disease. Inflamm Bowel Dis. 14; 652-661.
[52] Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass
MW, Conrad C (2011) Diagnostic value, clinical utility and pathogenic significance of
reactivity to the molecular targets of Crohn’s disease specific-pancreatic autoantibod‐
ies. Autoimmun Rev. 11; 143-148.
[53] Papp M, Norman GL, Altorjay I, Lakatos PL (2007) Utility of serological markers in
inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 14; 2028-2036.
[54] Malamat G, Verkarre V, Suarez F, Viallard J-F, Lascaux A-S, Cosnes J, Bouhnik Y,
Lambotte O, Bechade D, Ziol M, Lavergne A, Hermine O, Cerf-Bensussan N, Cellier
C 0(2010) The enteropathy associated with common variable immunodeficiency. Am
J Gastroenterol. 105; 2262-2275.
[55] Agarval S, Smereka P, Harpaz N, Cunnigham-Rundles Ch, Mayer L (2011) Charac‐
terization of immunologic defects in patients with common variable immunodefi‐
ciency (CVID) with intestinal disease. Inflamm Bowel Dis. 17; 251-259.
[56] Pituch-Noworolska A, Zwonarz K (2012) Celiac and inflammatory bowel diseases in
children with primary immunodeficiency. In: Autoimmune Disease. Ed. Chan J, In‐
Tech, chapter 7, pp. 151-172.
Autoimmunity in Children with Primary Immunodeficiency – Diagnosis, Management and Therapy
http://dx.doi.org/10.5772/60882
91
[57] Al-Muhsen SZ (2010) Gastrointestinal and hepatic manifestations of primary im‐
mune deficiency diseases. Saudi J Gastroenterol. 16; 66-74.
[58] Walker MM, Murray JA (2011) An update in the diagnosis of celiac disease. Histopa‐
thology. 59; 166-179.
[59] Schirbel A, Fiocchi C (2010) Inflammatory bowel disease: established and evolving
considerations on its etiopathogenesis and therapy. J Digest Dis. 11; 266-276.
[60] Glocker E, Grimbacher B (2012) Inflammatory bowel disease. Cell Mol Life Sci. 69;
41-48.
[61] Genre J, Errante PR, Kokron CM, Toledo-Barros M, Camara NOS, Rizzo LV (2009)
Reduced frequency of CD4+CD25highFoxP3+ cells and diminished FoxP3 expression
in patients with common variable immunodeficiency: a link to autoimmunity? Clin
Immunol. 132; 215-221.
[62] Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Ann Rev Immu‐
nol. 28; 573-621.
[63] Wang J, Cunningham-Rundles C (2005) Treatment and outcome of autoimmune
hematologic disease in common variable immunodeficiency (CVID). J Autoimmun.
25: 57-62.
[64] Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, Oksenhendler E,
Schaeffer A, Bierling P, Godeau B (2004) Autoimmune thrombocytopenic purpura
and common variable immunodeficiency. Medicine. 83: 254-263.
[65] Cunningham-Rundles Ch (2002) Hematologic complications of primary immune de‐
ficiencies. Blood Rev. 16; 61-64.
[66] Pituch-Noworolska A, Siedlar M, Kowalczyk D, Szaflarska A, Błaut-Szlósarczyk A,
Zwonarz K (2014) The effect of immunoglobulins substitution in common variable
immunodeficiency (CVID) with chronic thrombocytopenia. Congress of Polish Soci‐
ety of Clinical and Experimental Immunology, 24-26 June, Wrocław, Poland.
[67] Kaveri SV, Maddur MS, Hadge P, Lacroix-Desmazes S, Bayry J (2011) Intravenous
immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin
Exp Immunol. 164: 2-5.
[68] Al-Ahmad M, Al-Rasheed M, Al-Muhadi A (2010) Successful use of rituximab in re‐
fractory idiopathic thrombocytopenic purpura in a patient with common variable im‐
munodeficiency. J Investig Allergol Clin Immunol. 20: 259-262,
[69] Gobert D, Busel JB, Cunningham-Rundles C, Galicier L, Dechartes A, Berezne A,
Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M,
Seve P, Smail A, Viallard J-F, Godeau B, Hermine O, Mechel M (2011) Efficacy and
safety of rituximab in common variable immunodeficiency-associated cytopenias: a
retrospective multicentre study of 33 patients. Brit J Haematol. 155: 498-508.
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases92
[70] Pituch-Noworolska A (2014) The effect of immunoglobulins substitution in hyper
IgM syndrome. 7th International Immunoglobulins Conference 4-5 Apr, Interlaken,
Switzerland.
[71] Sokolic R (2013) Neutropenia in primary immunodeficiency. Curr Opin Hematol. 20;
55-65
[72] Nejad AR, Rostami K, Pourhoseingholi MA, Mojarad EN, Habibi M, Dabiri H, Zali
Mr (2009) Atypical presentation is dominant and typical for celiac disease. J Gastroin‐
testin Liver Dis. 18; 285-291.
[73] Valletta E, Fornaro M, Pecori S, Zanoni G (2011) Selective immunoglobulin A defi‐
ciency and celiac disease. J Invest Allergol Clin Immunol. 21; 242-244.
[74] Fabris M, De Vita S, Visentini D, Fabro C, Picierno A, Lerussi A, Villalta D, Alessio
MG, Tampoia MA, Tonutti E (2009) B-lymphocyte stimulator and a proliferation-in‐
ducting ligand serum levels in IgA-deficient patients with and without celiac disease.
Ann NY Acad Sci. 1173; 268-273.
[75] Borrelli M, Maglio M, Agnese M, Paparo F, Gentile S, Colicchio B, Tosco A, Auricchio
R, Troncone R (2009) High density of intraepithelial TCR γ/δ lymphocytes and de‐
posits of immunoglobulin (Ig)M anti tissue transglutaminase antibodies in the jeju‐
num of celiac patients with IgA deficiency. Clin Exp Immunol. 160; 199-206.
[76] Daniels JA, Lederman HM, Maitra A, Montgomery EA (2007) Gastrointestinal tract
pathology in patients with common variable immunodeficiency (CVID). Am J Surg
Pathol. 31; 1800-1812.
[77] Agarwal S, Mayer L (2013) Diagnosis and treatment of gastrointestinal disorders in
patients with primary immunodeficiency. Clin Gastroenterol Hepatol. 3; 1050-1063.
[78] Kobrynski LJ, Mayer L (2011) Diagnosis and treatment of primary immunodeficiency
disease in patients with gastrointestinal symptoms. Clin Immunol. 139; 238-248.
[79] Blutt SE, Conner ME (2013) The gastrointestinal frontiers: IgA and viruses. Front Im‐
munol. 4; art. 402.
[80] Makol A, Watt KD, Chowdhary VR (2011) Autoimmune hepatitis: a review of cur‐
rent diagnosis and treatment. Hepatitis Res Treat. Art. 390916; 1-11.
[81] Mieli-Vergani G, Vergani D (2008) Autoimmune paediatric liver disease. World J Gas‐
troenterol. 14; 3360-3367.
[82] Bergbreiter A, Salzer U (2009) Common variable immunodeficiency: a multifaceted
and puzzling disorder. Expert Rev Clin Immunol. 5; 167-180.
[83] Verbruggen G, De Backer S, Deforce P, Demetter P, Cuvelier C, Veys E, Elewaut D
(2005) X linked agammaglobulinemia and rheumatoid arthritis. Ann Rheum Dis. 64;
1075-1078.
Autoimmunity in Children with Primary Immunodeficiency – Diagnosis, Management and Therapy
http://dx.doi.org/10.5772/60882
93
[84] Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles Ch, Ochs HD, Bonilla
FA, Paris K, Yel L, Sullivan KE (2014) Autoimmunity and inflammation in X-linked
agammaglobulinemia. J Clin Immunol. 34; 627-632.
[85] Blanco-Quiros A, Solis-Sanchez P, Garrote-Adrados JA, Arranz-Sanz E (2006) Com‐
mon variable immunodeficiency. Old questions are getting clearer. Allergol Immuno‐
pathol. 34; 263-275.
[86] Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immu‐
noglobulin. Ann Rev Immunol. 26; 513-533.
[87] Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune re‐
sponses. Immunological Rev. 236; 265-275.
[88] Siedlar M, Strach M, Bukowska-Strakova K, Lenart M, Szaflarska A, Węglarczyk K,
Rutkowska M, Baj-Krzyworzeka M, Pituch-Noworolska A, Kowalczyk D, Grodzicki
T, Ziegler-Heitbrock L, Zembala M (2011) Preparations of intravenous immunoglo‐
bulins diminish the number and proinflammatory response of CD14+CD16+ mono‐
cytes in common variable immunodeficiency (CVID) patients. Clin Immunol.
139;122-132.
[89] Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-
Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Frid‐
man C, Hermine O, Kaveri SV (2011) Intravenous immunoglobulins induces
proliferation and immunoglobulin synthesis from patients with common immunode‐
ficiency. J Autoimmun 36: 9-15,
[90] Rezaei N, Abolhassani H, Aghamogammadi A, Ochs HD (2011) Indications and safe‐
ty of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immu‐
nol. 7; 301-316.
[91] Pituch-Noworolska A, Błaut-Szlósarczyk A, Zwonarz K (2010) Stosowanie prepara‐
tów immunoglobulin ludzkich – objawy niepożądane. In Polish. (The use of human
immunoglobulins – adverse reactions). Polski Merkuriusz Lekarski. 29; 202-205.
[92] Kobrynski L (2012) Subcutaneous immunoglobulin therapy. Biologics: Targ Ther. 6;
277-287.
[93] Pituch-Noworolska A, Błaut-Szlósarczyk A (2010) Immunoglobulins: characteristics,
indications for use and clinical effectiveness. Int Rev Allergol Clin Immunol. 16; 94-101.
[94] Haddad E, Barnes D, Kafal A (2012) Home therapy with subcutaneous immunoglo‐
bulins for patients with primary immunodeficiency diseases. Transf Apheresis Sci. 46;
315-321.
[95] Podjasek JC, Abraham RS (2012) Autoimmune cytopenias in common variable im‐
munodeficiency. Front Immunol. 3: art. 189; 1-7.
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases94
[96] Nijeboer P, van Wanrooij RLJ, Tack GJ, Mulder CJJ, Bouma G (2013) Update of the
diagnosis and management of refractory celiac disease. Rev Gastroenterol Res Pract.
Art. 518 483.
[97] Al-Toma A, Verbeek WHM, Mulder CJJ (2007) The management of complicated cel‐
iac disease. Dig Dis. 25; 230-236.
[98] Tennyson Ch, Green PHH (2011) The role of capsule endoscopy in patients with non‐
responsive celiac disease. Gastrointest Endosc 74; 1323-1324.
[99] Sandhu BK, Fell JME, Beattie RM, Mitton SG, Wilson DC, Jenkins H (2010) Guide‐
lines for the management of inflammatory bowel disease in children in the United
Kingdom. J Ped Gastroenterol Nutri. 50; S1-S13.
[100] Burroughs L, Woolfrey A (2010) Hematopoietic cell transplantation for treatment of
primary immune deficiencies. Cell Ther Transplant. doi:10.3205/ctt-2010-en-000077.01.
[101] Cole TS, Johnstone IC, Pearce MS, Fulton B, Fulton B, Cant AJ, Gennery AR, Slatter
MA (2012) Outcome of children requiring intensive care following haematopoietic
SCT for primary immunodeficiency and other non-malignant disorders. BMT 47;
40-45.
[102] Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, Amrolia PJ, Gaspar
B, Davies EG, Friedrich W, Hoenig M, Notarangelo LD, Mazzolari E, Porta F, Bredius
RGM, Lankester AC, Wulffraat NM, Seger R, Gungor T, Fasth A, Sedlacek P, Neven
B, Blanche S, Fischer A, Cavazzana-Calvo, Landais P (2010) Transplantation of hae‐
matopoietic stem cells and long-term survival for primary immunodeficiencies. Eur J
Allergy Clin Immunol. 126; 602-610.
[103] Filipovich AH (2008) Hematopoietic cell transplantation for correction of primary
immunodeficiencies. BMT 42; S49-S52.
[104] De la Morena MT (2013) Recent advances in transplantation for primary immune de‐
ficiency diseases. Clin Rev Allergy Immune. doi: 10.1007/s12016-013-8379-6.
[105] Cha S-I, Fessler MB, Cool CD, Schwarz MI, Brown KK (2006) Lymphoid interstitial
pneumonia: clinical features, associations and prognosis. Eur Respir J. 28; 364-369.
[106] Matsubara M, Koizumi T, Wakamatsu T, Fujimoto K, Kubo K, Honda T (2008) Lym‐
phoid interstitial pneumonia associated with common variable immunoglobulin de‐
ficiency. Inter Med. 47; 763-767.
Autoimmunity in Children with Primary Immunodeficiency – Diagnosis, Management and Therapy
http://dx.doi.org/10.5772/60882
95

